Organization Overview
Historical Acquisition Tree
Alternative names
adagrasib (Krazati) (2022 NDA)
Key: Mirati Therapeutics Inc. (11) Acquired (1)
Key: Mirati Therapeutics Inc. (9) Acquired (6)
Key: Mirati Therapeutics Inc. (16) Acquired (1)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 1)
Carcinoma, Transitional Cell (Phase 2)
Hodgkin Disease (Phase 2)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Liposarcoma (Phase 2)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Mouth Neoplasms (Phase 1)
Myelodysplastic Syndromes (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Preleukemia (Phase 2)
Prostatic Neoplasms (Phase 1)
Rhabdomyosarcoma (Phase 1)
Sarcoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Stomach Neoplasms (Phase 1)
Syndrome (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)